In the evolving field of drug delivery systems, thermosensitive liposomes (TSLs) have emerged as a promising technology. But what about the excipients used in those liposomes? Specifically, what is a thermosensitive liposome excipient, and why is it essential to ensure efficacy, safety, and controlled drug release? In this article we explore this question in depth, drawing on recent research, mechanistic insights, and implications for development by companies like AVT Pharmaceutical.
What Are Thermosensitive Liposomes and What Is an Excipient?
Understanding Thermosensitive Liposomes
Thermosensitive liposomes are lipid‐based vesicular systems engineered to encapsulate therapeutic agents, which remain stable under normal physiological conditions (≈ 37 °C), but release their payload when exposed to elevated (hyperthermic) temperatures—typically in the range of 40-43 °C.
This triggered release allows for locally targeted treatment, reducing systemic side effects and improving drug accumulation in desired tissues (e.g. tumors) when hyperthermia can be applied.
Defining Excipient in This Context
An excipient in pharmaceutical formulations refers to any component besides the active drug, which supports the delivery, stability, or performance of the drug product. For thermosensitive liposomes, excipients include lipids, cholesterol, PEGylated lipids, surfactants, and stabilizers. The thermosensitive liposome excipient is one (or more) of these ingredients that enable or modulate the thermosensitivity, stability, release kinetics, circulation time, and biocompatibility of the liposome.
Why Are Thermosensitive Liposome Excipients Crucial?
Phase Transition‐Control and Triggered Release
A major role of excipients is to define the phase transition temperature (Tₘ) of the liposomal bilayer. The lipid constituents are selected such that below Tₘ the liposome membrane is relatively stable (gel / ordered state) and above Tₘ it becomes more fluid (liquid‐crystalline), enabling rapid drug release. For example:
-
DPPC (1,2‐dipalmitoyl‐sn‐glycero‐3‐phosphocholine) has a Tₘ around 41-42 °C and is commonly used in TSL formulations.
-
Addition of lipids with longer acyl chains or saturated lipids increases Tₘ, while incorporation of lipids with unsaturated chains or shorter lengths lowers Tₘ. Adjustments via cholesterol content also modulate membrane fluidity.
Thus, the thermosensitive liposome excipient selection is central in achieving the correct trigger temperature—high enough to avoid premature release, but low enough to be safely and practically achieved in hyperthermia settings.
Stability, Circulation Time, and Biocompatibility
Beyond temperature control, excipients affect:
-
Stability in circulation: Lipids prone to oxidation, or liposomes without stabilizing excipients, may degrade or release drug prematurely.
-
PEGylation (PEG-lipids as excipients): Provides “stealth” behavior, reducing opsonization and clearance by the reticuloendothelial system (RES), increasing circulation time. For example, PEG2000‐DSPE is often used.
-
Safety / toxicity: Excipients must be non‐immunogenic, non‐toxic, and free of harmful impurities. Regulatory expectations (e.g. for liposomal drug products) often require characterization of phospholipids, cholesterol, and other excipient purity.
Drug Loading, Release Kinetics, and Targeting
How quickly the liposome releases its payload upon heating is influenced heavily by excipient composition:
-
Lipid chain length, saturation, presence of destabilizing lipids or lysolipids can increase permeability when heated.
-
Excipients can also influence whether drug release is extravascular (after accumulation in tissue via enhanced permeability and retention, EPR) or intravascular (release in the microvasculature while liposomes traverse heated tissue). The design (including excipient selection) plays a role here.
https://www.avt-pharma.com/Liposome-Excipients
AVT Pharmaceutical
About Author
